Dose adjustment in renal impairment
Dose adjustment may be needed in kidney disease.
Leaflet RUNAPLAX 15mg film-coated tablets
- Product code:
- W70050019
- Quantity:
- 100
- Indicated for:
- prevention and treatment of thromboembolism
- Route of administration:
- oral
- Substance:
- rivaroxaban (anticoagulant)
- ATC
- B01AF01 — Blood and blood forming organs | Antithrombotic agents | Antithrombotic agents | Direct factor xa inhibitors
Precautions:
Major drug interactions
This medicine may have important interactions with other medicines.
Additional monitoring
This medicine is subject to additional monitoring.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.
Bleeding risk
This medicine may increase the risk of bleeding.
Rivaroxaban is a direct oral anticoagulant that inhibits factor Xa, an essential enzyme in the coagulation cascade. It is used for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and to reduce the risk of stroke in patients with non-valvular atrial fibrillation.
Rivaroxaban is administered orally, usually once daily, and has the advantage of not requiring regular INR (international normalized ratio) monitoring, unlike traditional anticoagulants such as warfarin. It is also indicated for the prevention of thromboembolic events following major orthopedic surgeries, such as hip or knee replacement.
Common side effects include bleeding, anemia, nausea, and dizziness. In rare cases, severe bleeding or allergic reactions may occur. It is important for patients to inform their healthcare provider about any other medications or supplements they are taking, as interactions may increase the risk of bleeding.
Rivaroxaban is a modern and effective option for the prevention and treatment of thromboembolic events, offering improved safety and convenience for patients.
Rivaroxaban is administered orally, usually once daily, and has the advantage of not requiring regular INR (international normalized ratio) monitoring, unlike traditional anticoagulants such as warfarin. It is also indicated for the prevention of thromboembolic events following major orthopedic surgeries, such as hip or knee replacement.
Common side effects include bleeding, anemia, nausea, and dizziness. In rare cases, severe bleeding or allergic reactions may occur. It is important for patients to inform their healthcare provider about any other medications or supplements they are taking, as interactions may increase the risk of bleeding.
Rivaroxaban is a modern and effective option for the prevention and treatment of thromboembolic events, offering improved safety and convenience for patients.
General data about RUNAPLAX 15mg
- Substance:
- rivaroxaban
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W70050019
- Concentration:
- 15mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 100
- Product type:
- Generic medicine
- Price:
- 250.90 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for rivaroxaban
Concentrations available for rivaroxaban
- 10mg
- 15mg
- 15mg+20mg
- 2.5mg
- 20mg
Combinations with other substances
Compensation lists for RUNAPLAX 15mg Sanpha
B - Sublist B with 50% discount from the reference price
- Price
- 250.90 RON
- Copayment
- 114.41 RON
- Patient
- 136.49 RON